Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7713090 | 0.83 | ALDH1A1 (0.33) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL668926 | 0.76 | CYP3A4 (0.32) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3549256 | 0.73 | APLNR (0.32) | — | |
| SCHEMBL669391 | 0.72 | MAPT (0.35) | KDM4EMEN1MAPTALOX15KMT2A | |
| SCHEMBL670372 | 0.72 | — | — | |
| SCHEMBL24868147 | 0.70 | — | — | |
| SCHEMBL4645147 | 0.70 | — | — | |
| SCHEMBL669585 | 0.68 | USP2 (0.33) | MAPT | |
| SCHEMBL3958433 | 0.67 | GRM2 (0.32) | — | |
| SCHEMBL3958437 | 0.67 | GRM2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759454-B2 | Diazole lactams | CHEMOCENTRYX, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20210093613-A1 | DIAZOLE LACTAMS | CHEMOCENTRYX, INC. | 2021-04-01 | — | — | US | disclosed |
| US-10744118-B2 | Diazole lactams | CHEMOCENTRYX, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| EP-2928474-B1 | DIAZOLE LACTAMS | CHEMOCENTRYX INC (US) | 2018-11-14 | — | — | EP | disclosed |
| US-20160303084-A1 | DIAZOLE LACTAMS | CHEMOCENTRYX, INC. | 2016-10-20 | — | — | US | disclosed |
| EP-2928474-A1 | DIAZOLE LACTAMS | ChemoCentryx, Inc. (US) | 2015-10-14 | — | — | EP | disclosed |
| WO-2014089495-A1 | DIAZOLE LACTAMS | CHEMOCENTRYX, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| EP-0971588-B1 | NOVEL CANNABINOID RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORP (US) | 2004-03-17 | — | — | EP | disclosed |
| EP-0971588-A4 | NOVEL CANNABINOID RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORP (US) | 2000-12-27 | — | — | EP | disclosed |
| US-6100259-A | 1-(DISUBSTITUTED PHENYL)4,5-SUBSTITUTED PYRAZOLE DERIVATIVES OF GIVEN FORMULA; ANTAGONIZING CANNABINOID 2 RECEPTORS; TREATING RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS, PSORIASIS, MULTIPLE SCLEROSIS, DIABETES AND THYROIDITIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-08 | — | — | US | disclosed |
| EP-0971588-A1 | NOVEL CANNABINOID RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998031227-A1 | NOVEL CANNABINOID RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303084-A1 | DIAZOLE LACTAMS | CCR1, CCRL2, CCR4 | PDE4A 1403/4885PDE4B 1437/4885PDE4C 1973/4885 |
| US-20210093613-A1 | DIAZOLE LACTAMS | CCR1, CCRL2, CCR4 | PDE4A 1403/4885PDE4B 1437/4885PDE4C 1973/4885 |
| US-10744118-B2 | Diazole lactams | CCR1, CCRL2, CCR4 | PDE4A 1403/4885PDE4B 1437/4885PDE4C 1973/4885 |
| US-11759454-B2 | Diazole lactams | CCR1, CCRL2, CCR4 | PDE4A 1403/4885PDE4B 1437/4885PDE4C 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.